Jessica Steen, OD, FAAO

EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.

Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.

Optometrists are often the first to notice ocular adverse effects from systemic medication. When should optometrists reach out to prescribing doctors?

Evaluating images for quality, artifacts, and segmentation errors.

Novel drops for a variety of indications are under investigation.

Jessica Steen, OD, FAAO, gave an ophthalmic therapeutic update during the 2022 American Academy of Optometry Meeting.

Jessica Steen, OD, FAAO, shares what she wishes she knew before entering the field.

Jessica Steen, OD, FAAO, shares highlights from her VEW 2022 presentation, "Ophthalmic therapeutics update."

Jessica Steen, OD, FAAO, shares key takeaways from her AOA 2022 presentation, "Problem Solving in Glaucoma Management."

Jessica Steen, OD, FAAO, shares why she views the development of OCT-angiography as her personal favorite technological advancement in eyecare.

FDA review pathway looks to balance innovation with data review

Use of intravitreal biologics, steroids, and improvements to vitreoretinal surgical techniques have improved the prognosis of vitreoretinal conditions. Ocular hypertension, which may lead to secondary open-angle glaucoma, is a common complication both short- and long-term following intravitreal injection of anti-VEGF or steroid agent and PPV—especially when silicone oil is used as a tamponade agent. Understanding these potential risks is key to early detection, diagnosis, and management following vitreoretinal procedures.